Daratumumab-Associated Infections in Multiple Myeloma
Daratumumab significantly increases the risk of infections, particularly upper respiratory tract infections, pneumonia, and opportunistic viral reactivations including cytomegalovirus (CMV) and varicella-zoster virus (VZV), requiring universal herpes virus prophylaxis and vigilant monitoring.
Types of Infections Associated with Daratumumab
Bacterial Infections
Upper respiratory tract infections and pneumonia are the most common bacterial complications. In the POLLUX study, daratumumab combined with lenalidomide-dexamethasone was associated with increased upper respiratory tract infections compared to controls 1. A 2025 meta-analysis demonstrated that daratumumab-based regimens increase the risk of any infection (RR 1.23), grade ≥3 infections (RR 1.29), and specifically pneumonia (RR 1.60) 2.
- Pneumonia occurs in 11-19% of patients on daratumumab-containing regimens 3, 4
- Grade 3-4 infections range from 21-37% depending on the combination regimen 4
- Fatal infections remain uncommon (≤2%) and are primarily due to pneumonia and sepsis 4
Viral Infections
Herpes virus reactivations represent a critical concern with daratumumab therapy. The FDA label specifically addresses this risk 4.
Herpes Zoster Virus (VZV)
- Reported in 2-5% of patients in combination therapy studies 4
- Can present as disseminated infection with gastrointestinal prodromal symptoms (anorexia, vomiting, fever) before characteristic skin lesions appear 5
- Universal VZV prophylaxis is recommended 6
Cytomegalovirus (CMV)
CMV reactivation is significantly more frequent with daratumumab than previously recognized. Recent real-world data shows:
- CMV reactivation occurs in 17-33% of daratumumab-treated patients versus 2.5-4% in controls 7, 8
- Cumulative incidence at 6 months: 18.1% in newly diagnosed MM patients 9
- Median time to CMV infection: 27 days after first daratumumab infusion 7
- CMV disease (e.g., retinitis, pneumonia) is rare but serious 9, 10
Risk factors for CMV/EBV infection during daratumumab:
- Lower baseline albumin levels 7
- Lower baseline lymphocyte counts 7
- Depletion of NK cells, total T cells, and CD8+ T cells at 1-2 months post-initiation 7
Hepatitis B Virus (HBV)
- HBV reactivation reported in <1% of patients but can be fatal 4
- Screen all patients for HBV reactivation risk before starting therapy 6
Opportunistic Infections
The 2023 expert consensus on bispecific antibody therapy (which shares similar immunosuppressive mechanisms with daratumumab) provides relevant guidance 6:
- Universal Pneumocystis jirovecii pneumonia (PJP) prophylaxis is recommended 6
- No routine antifungal prophylaxis is recommended 6
Monitoring Strategy
Baseline Assessment
- Complete blood count with differential - establish baseline neutrophil, lymphocyte, and platelet counts 4
- Immunoglobulin levels - assess for hypogammaglobulinemia 11
- HBV serologies - screen all patients 6
- CMV serology - identify at-risk patients 9
During Treatment Monitoring
For neutropenia and cytopenias:
- Monitor CBC periodically throughout treatment 4
- Dose delays may be required for neutrophil or platelet recovery 4
- Consider G-CSF for Grade 3 neutropenia 6
For viral reactivations:
- CMV monitoring: Consider regular CMV antigenemia or PCR testing, particularly in the first 2-3 months 9, 7, 8
- Monitor for early signs: fever, respiratory symptoms, gastrointestinal symptoms 9, 5
- Lower threshold for testing in patients with low lymphocyte counts or albumin 7
For immunoglobulin deficiency:
- Monitor immunoglobulin levels monthly 6
- Patients with multiple myeloma have functional hypogammaglobulinemia that worsens with daratumumab 11
Management Approach
Prophylaxis (Universal Recommendations)
Implement these prophylactic measures for ALL patients starting daratumumab:
- Herpes virus prophylaxis - acyclovir or valacyclovir throughout treatment 6, 4
- PJP prophylaxis - trimethoprim-sulfamethoxazole or alternative 6
- Consider monthly IVIG for hypogammaglobulinemia in absence of life-threatening infections 6
Treatment of Active Infections
For CMV reactivation:
- Asymptomatic CMV antigenemia: Most cases (89%) can be managed with observation alone 9
- Symptomatic or high viral load (>1000 IU/mL): Preemptive valganciclovir therapy 8
- CMV disease: Intravenous ganciclovir; consider combination with intravitreal therapy for retinitis if systemic therapy not tolerated 10
For bacterial infections:
- Prompt empiric broad-spectrum antibiotics for febrile neutropenia
- Same-day evaluation for any new respiratory symptoms or fever 12
- Lower threshold for hospitalization given increased pneumonia risk
For VZV:
- Disseminated VZV requires immediate IV acyclovir 5
- High suspicion needed when gastrointestinal symptoms precede rash 5
Dose Modifications
Interrupt daratumumab for:
- Active Grade 3-4 infections until resolution
- Severe neutropenia with infection
- Infusion-related reactions of any severity 4
Critical Pitfalls to Avoid
Underestimating CMV risk: Recent data shows 6-8 fold higher CMV reactivation rates than previously reported 7, 8. Consider routine monitoring rather than symptom-driven testing.
Missing atypical VZV presentations: Disseminated VZV may present with gastrointestinal symptoms (anorexia, vomiting) days before skin lesions appear 5.
Delaying evaluation of respiratory symptoms: The combination of teclistamab plus daratumumab shows synergistic infection risk, particularly for pneumonia and influenza 12. Any respiratory symptom warrants same-day assessment.
Inadequate prophylaxis: Universal herpes virus and PJP prophylaxis are non-negotiable given the immunosuppressive mechanism of CD38 depletion 6, 4.
Ignoring immunoglobulin levels: Daratumumab worsens the functional hypogammaglobulinemia inherent to multiple myeloma 11. Monthly monitoring and IVIG replacement prevent recurrent sinopulmonary infections.